Immunoassay Market Outlook: Industry to Reach USD 47.76 Billion by 2030
The global immunoassay market is witnessing steady and sustained growth as healthcare systems worldwide place greater emphasis on early, accurate, and scalable diagnostic solutions. Immunoassays remain one of the most widely used diagnostic technologies, enabling sensitive detection of diseases across infectious, chronic, and lifestyle-related conditions.
The immunoassay market is projected to grow from USD 35.53 billion in 2025 to USD 47.76 billion by 2030, registering a compound annual growth rate (CAGR) of 6.1%. This growth is driven by the rising prevalence of chronic and infectious diseases, increasing demand for early disease diagnosis, advancements in automation and high-throughput technologies, and expanding adoption of immunoassay-based point-of-care testing.
Market Drivers Supporting Sustained Growth
Immunoassays play a critical role in modern diagnostics due to their high sensitivity, specificity, and versatility. Several factors are fueling market expansion:
- Growing global burden of infectious diseases and chronic conditions such as cancer, cardiovascular disorders, diabetes, and autoimmune diseases
- Increasing focus on early diagnosis and preventive healthcare
- Technological advancements in assay sensitivity, multiplexing, and automation
- Rising demand for decentralized testing through point-of-care and home-based diagnostics
- Expanding applications in therapeutic drug monitoring and personalized medicine
Together, these trends are reinforcing immunoassays as essential tools across clinical diagnostics and laboratory medicine.
Reagents and Kits Dominate the Product Landscape
By product, the immunoassay market comprises reagents & kits and analyzers. In 2024, the reagents & kits segment dominated the market, driven by their indispensable role in diagnostic workflows.
Reagents and kits are consumables used repeatedly across routine and specialized testing, ensuring:
- High assay accuracy and sensitivity
- Consistent test performance
- Continuous demand from hospitals, laboratories, and blood banks
While reagents and kits account for the largest revenue share, analyzers are gaining traction due to the increasing adoption of automation and high-throughput laboratory systems. Automated analyzers improve turnaround time, reduce manual errors, and enhance workflow efficiency, making them critical for large diagnostic laboratories and centralized testing facilities.
ELISA Leads Among Immunoassay Technologies
The immunoassay market encompasses a broad range of technologies, including enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, Western blotting, and other emerging platforms.
In 2024, ELISA dominated the immunoassay market by technology, owing to its:
- High sensitivity and specificity
- Cost-effectiveness
- Standardized protocols
- Compatibility with high-throughput laboratory workflows
ELISA is widely used across infectious disease testing, oncology, endocrinology, and drug monitoring. Meanwhile, CLIA, IFA, and rapid tests are witnessing growing adoption due to advances in automation, multiplexing, and point-of-care capabilities, enabling faster and more precise diagnostics in both clinical and decentralized settings.
Blood Remains the Primary Diagnostic Specimen
By specimen type, immunoassays utilize blood, saliva, urine, and other specimens. In 2024, blood accounted for the largest market share, driven by its reliability, ease of collection, and ability to provide accurate and reproducible diagnostic results.
Blood-based immunoassays remain the gold standard for a wide range of applications, including infectious diseases, oncology, endocrinology, and cardiology. However, non-invasive specimens such as saliva and urine are gaining momentum, particularly for:
- Patient-friendly testing
- Home-based diagnostics
- Therapeutic drug monitoring
Other specimens, including cerebrospinal fluid and tissue samples, are used in specialized clinical and research applications.
Infectious Diseases Lead by Application
By application, the immunoassay market covers infectious diseases, endocrinology, oncology, bone and mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, drug monitoring, newborn screening, and other uses.
In 2024, infectious diseases represented the largest application segment, driven by:
- Rising prevalence of viral and bacterial infections
- High demand for rapid and accurate diagnostic tests
- Routine screening and outbreak management needs
Other applications such as oncology and endocrinology are growing steadily due to increasing cancer incidence, hormonal disorders, and the expanding use of immunoassays for early detection, disease monitoring, and personalized treatment strategies.
Hospitals and Clinics Lead End-User Adoption
By end user, the immunoassay market includes hospitals & clinics, clinical laboratories, blood banks, and home care settings. In 2024, hospitals and clinics held the largest market share, reflecting the high volume of routine and specialized diagnostic testing performed in these environments.
Clinical laboratories are rapidly adopting immunoassay platforms for high-throughput and automated testing, while blood banks rely on immunoassays for infectious disease screening. At the same time, home care settings are emerging as a high-growth segment, supported by the rising adoption of point-of-care immunoassay devices that enable convenient and rapid testing outside traditional clinical settings.
Regional Market Trends
The immunoassay market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Growth dynamics vary across regions:
- North America and Europe benefit from strong healthcare infrastructure, technological innovation, and high adoption of advanced diagnostics
- Asia Pacific is witnessing rapid expansion due to government investments, rising disease burden, and growing diagnostic capacity
- Latin America is seeing improved healthcare access and affordability
- Middle East & Africa are experiencing increased adoption of point-of-care testing amid rising disease prevalence
Competitive Landscape and Strategic Developments
Major players in the immunoassay market are pursuing organic and inorganic growth strategies, including partnerships, collaborations, and investments in R&D. For instance, F. Hoffmann-La Roche Ltd. expanded its collaboration with Janssen Biotech Inc., strengthening joint development across multiple companion diagnostics technologies, including immunoassays, IHC, digital pathology, PCR, and NGS.
Such collaborations are accelerating innovation, expanding test portfolios, and supporting the development of precision diagnostics.
Market Outlook
The immunoassay market is poised for continued growth as diagnostic needs expand across infectious diseases, oncology, and chronic condition management. Technological innovations such as high-sensitivity chemiluminescence assays, multiplex platforms, and automated systems are transforming diagnostic accuracy and efficiency.
With increasing emphasis on early detection, personalized medicine, and decentralized testing, immunoassays will remain a cornerstone of global diagnostics, driving sustained market growth through 2030 and beyond.